163 related articles for article (PubMed ID: 23048077)
21. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
22. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
Witzig TE; Reeder C; Han JJ; LaPlant B; Stenson M; Tun HW; Macon W; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic S; Nowakowski GS; Gupta M
Blood; 2015 Jul; 126(3):328-35. PubMed ID: 25921059
[TBL] [Abstract][Full Text] [Related]
23. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
24. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
[TBL] [Abstract][Full Text] [Related]
26. Targeting the bone marrow in Waldenstrom macroglobulinemia.
Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa GC; Leleu X; Roccaro AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S65-9. PubMed ID: 22035751
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Redd R; Armand P; Banwait R; Boswell E; Chuma S; Huynh D; Sacco A; Roccaro AM; Perilla-Glen A; Noonan K; MacNabb M; Leblebjian H; Warren D; Henrick P; Castillo JJ; Richardson PG; Matous J; Weller E; Treon SP
Leukemia; 2015 Dec; 29(12):2338-46. PubMed ID: 26139427
[TBL] [Abstract][Full Text] [Related]
28. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Ngo HT; Azab AK; Farag M; Jia X; Melhem MM; Runnels J; Roccaro AM; Azab F; Sacco A; Leleu X; Anderson KC; Ghobrial IM
Clin Cancer Res; 2009 Oct; 15(19):6035-41. PubMed ID: 19755386
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Husu EN; Pitsillides C; Vesole S; Azab AK; Azab F; Melhem M; Ngo HT; Quang P; Maiso P; Runnels J; Liang MC; Wong KK; Lin C; Ghobrial IM
Blood; 2010 Jan; 115(3):559-69. PubMed ID: 19965685
[TBL] [Abstract][Full Text] [Related]
30. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
33. Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm.
Nishino M; Boswell EN; Hatabu H; Ghobrial IM; Ramaiya NH
Oncologist; 2015 Sep; 20(9):1077-83. PubMed ID: 26205737
[TBL] [Abstract][Full Text] [Related]
34. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
35. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
36. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
[TBL] [Abstract][Full Text] [Related]
38. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
39. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Ghobrial IM; Siegel DS; Vij R; Berdeja JG; Richardson PG; Neuwirth R; Patel CG; Zohren F; Wolf JL
Am J Hematol; 2016 Jun; 91(4):400-5. PubMed ID: 26800393
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
